Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Valeo Pharma
Kirkland, Quebec, Canadavaleopharma.com ↗
- Ownership
- Private
- Employees
- ~60
- Development stage
- Other
01
Overview
As of early February 2025, Valeo Pharma has a portfolio of approximately twelve commercialized products across respiratory/allergy, ophthalmology, neurology, oncology, and specialty hospital products. The company has demonstrated significant revenue growth over the past three years with a focus on licensing/acquiring Canadian rights to innovative drugs. In February 2025 it was acquired by Xediton Pharmaceuticals Inc., which will continue operating the business under its existing structure.[1–6]
- Therapeutic areas
- PulmonologyCardiovascularOphthalmologyImmunologyDermatologyOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculeBiologicDeviceFlavonoid formulation
- Industry
- Biotech
02
Partnerships
Novartis/SandozVeru
Beyond the preview
Go deeper on Valeo Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Valeo Pharma.